225 related articles for article (PubMed ID: 27560968)
1. Renal Dysfunction during Tenofovir Use in a Regional Cohort of HIV-Infected Individuals in the Asia-Pacific.
Tanuma J; Jiamsakul A; Makane A; Avihingsanon A; Ng OT; Kiertiburanakul S; Chaiwarith R; Kumarasamy N; Nguyen KV; Pham TT; Lee MP; Ditangco R; Merati TP; Choi JY; Wong WW; Kamarulzaman A; Yunihastuti E; Sim BL; Ratanasuwan W; Kantipong P; Zhang F; Mustafa M; Saphonn V; Pujari S; Sohn AH;
PLoS One; 2016; 11(8):e0161562. PubMed ID: 27560968
[TBL] [Abstract][Full Text] [Related]
2. Renal function in Ethiopian HIV-positive adults on antiretroviral treatment with and without tenofovir.
Yilma D; Abdissa A; Kæstel P; Tesfaye M; Olsen MF; Girma T; Ritz C; Friis H; Andersen ÅB; Kirk O
BMC Infect Dis; 2020 Aug; 20(1):582. PubMed ID: 32762646
[TBL] [Abstract][Full Text] [Related]
3. Effect of Tenofovir Disoproxil Fumarate on Incidence of Chronic Kidney Disease and Rate of Estimated Glomerular Filtration Rate Decrement in HIV-1-Infected Treatment-Naïve Asian Patients: Results from 12-Year Observational Cohort.
Suzuki S; Nishijima T; Kawasaki Y; Kurosawa T; Mutoh Y; Kikuchi Y; Gatanaga H; Oka S
AIDS Patient Care STDS; 2017 Mar; 31(3):105-112. PubMed ID: 28282247
[TBL] [Abstract][Full Text] [Related]
4. Is Abnormal Urine Protein/Osmolality Ratio Associated with Abnormal Renal Function in Patients Receiving Tenofovir Disoproxil Fumarate?
Marcelin JR; Berg ML; Tan EM; Amer H; Cummins NW; Rizza SA
PLoS One; 2016; 11(2):e0149562. PubMed ID: 26872144
[TBL] [Abstract][Full Text] [Related]
5. Impact of a tenofovir disoproxil fumarate plus ritonavir-boosted protease inhibitor-based regimen on renal function in HIV-infected individuals: a prospective, multicenter study.
Cao Y; Han Y; Xie J; Cui Q; Zhang L; Li Y; Li Y; Song X; Zhu T; Li T
BMC Infect Dis; 2013 Jul; 13():301. PubMed ID: 23815472
[TBL] [Abstract][Full Text] [Related]
6. Effect of baseline renal function on tenofovir-containing antiretroviral therapy outcomes in Zambia.
Mulenga L; Musonda P; Mwango A; Vinikoor MJ; Davies MA; Mweemba A; Calmy A; Stringer JS; Keiser O; Chi BH; Wandeler G;
Clin Infect Dis; 2014 May; 58(10):1473-80. PubMed ID: 24585558
[TBL] [Abstract][Full Text] [Related]
7. Proximal renal tubular function in HIV-infected children on tenofovir disoproxil fumarate for treatment of HIV infection at two tertiary hospitals in Harare, Zimbabwe.
Mashingaidze-Mano R; Bwakura-Dangarembizi MF; Maponga CC; Morse GD; Monera-Penduka TG; Mtisi TJ; Mudzviti T; Mujuru HA
PLoS One; 2020; 15(7):e0235759. PubMed ID: 32634168
[TBL] [Abstract][Full Text] [Related]
8. Chronic kidney disease and HIV in the era of antiretroviral treatment: findings from a 10-year cohort study in a west African setting.
Kaboré NF; Poda A; Zoungrana J; Da O; Ciaffi L; Semdé A; Yaméogo I; Sawadogo AB; Delaporte E; Meda N; Limou S; Cournil A
BMC Nephrol; 2019 May; 20(1):155. PubMed ID: 31064340
[TBL] [Abstract][Full Text] [Related]
9. Renal outcomes in patients initiated on tenofovir disoproxil fumarate-based antiretroviral therapy at a community health centre in Malawi.
Chikwapulo B; Ngwira B; Sagno JB; Evans R
Int J STD AIDS; 2018 Jun; 29(7):650-657. PubMed ID: 29334883
[TBL] [Abstract][Full Text] [Related]
10. Kidney dysfunction associated with tenofovir exposure in human immunodeficiency virus-1-infected Taiwanese patients.
Huang YS; Chan CK; Tsai MS; Lee KY; Lin SW; Chang SY; Hung CC; Chang SC
J Microbiol Immunol Infect; 2017 Oct; 50(5):595-603. PubMed ID: 26514942
[TBL] [Abstract][Full Text] [Related]
11. Changes in renal function with long-term exposure to antiretroviral therapy in HIV-infected adults in Asia.
Joshi K; Boettiger D; Kerr S; Nishijima T; Van Nguyen K; Ly PS; Lee MP; Kumarasamy N; Wong W; Kantipong P; Cuong DD; Kamarulzaman A; Choi JY; Zhang F; Chaiwarith R; Ng OT; Kiertiburanakul S; Sim BLH; Merati TP; Yunihastuti E; Ditangco R; Ross J; Pujari S
Pharmacoepidemiol Drug Saf; 2018 Nov; 27(11):1209-1216. PubMed ID: 30246898
[TBL] [Abstract][Full Text] [Related]
12. Incidence and risk factors for tenofovir-associated nephrotoxicity among human immunodeficiency virus-infected patients in Korea.
Lee JE; Lee S; Song SH; Kwak IS; Lee SH
Korean J Intern Med; 2019 Mar; 34(2):409-417. PubMed ID: 29020764
[TBL] [Abstract][Full Text] [Related]
13. Incidence and risk factors for tenofovir-associated renal toxicity in HIV-infected patients.
Quesada PR; Esteban LL; García JR; Sánchez RV; García TM; Alonso-Vega GG; Ferrández JS
Int J Clin Pharm; 2015 Oct; 37(5):865-72. PubMed ID: 26008219
[TBL] [Abstract][Full Text] [Related]
14. Incomplete reversibility of estimated glomerular filtration rate decline following tenofovir disoproxil fumarate exposure.
Jose S; Hamzah L; Campbell LJ; Hill T; Fisher M; Leen C; Gilson R; Walsh J; Nelson M; Hay P; Johnson M; Chadwick D; Nitsch D; Jones R; Sabin CA; Post FA;
J Infect Dis; 2014 Aug; 210(3):363-73. PubMed ID: 24585896
[TBL] [Abstract][Full Text] [Related]
15. Risk of Nephrotoxicity in Patients With Drug-Resistant Tuberculosis Treated With Kanamycin/Capreomycin With or Without Concomitant Use of Tenofovir-Containing Antiretroviral Therapy.
Perumal R; Abdelghani N; Naidu N; Yende-Zuma N; Dawood H; Naidoo K; Singh N; Padayatchi N
J Acquir Immune Defic Syndr; 2018 Aug; 78(5):536-542. PubMed ID: 29683992
[TBL] [Abstract][Full Text] [Related]
16. The effect of Tenofovir on renal function among Ugandan adults on long-term antiretroviral therapy: a cross-sectional enrolment analysis.
Salome T; Kasamba I; Mayanja BN; Kazooba P; Were J; Kaleebu P; Munderi P;
AIDS Res Ther; 2016; 13(1):28. PubMed ID: 27582777
[TBL] [Abstract][Full Text] [Related]
17. Renal function in HIV-infected children and adolescents treated with tenofovir disoproxil fumarate and protease inhibitors.
Pontrelli G; Cotugno N; Amodio D; Zangari P; Tchidjou HK; Baldassari S; Palma P; Bernardi S
BMC Infect Dis; 2012 Jan; 12():18. PubMed ID: 22269183
[TBL] [Abstract][Full Text] [Related]
18. Changes in estimated glomerular filtration rate over time in South African HIV-1-infected patients receiving tenofovir: a retrospective cohort study.
De Waal R; Cohen K; Fox MP; Stinson K; Maartens G; Boulle A; Igumbor EU; Davies MA
J Int AIDS Soc; 2017 Apr; 20(1):21317. PubMed ID: 28406595
[TBL] [Abstract][Full Text] [Related]
19. Lipid profile and renal safety of tenofovir disoproxil fumarate-based anti-retroviral therapy in HIV-infected Chinese patients.
Yang J; Chen J; Ji Y; Tang Q; Zhang R; Liu L; Shen Y; Xun J; Song W; Tang Y; Wang Z; Qi T; Lu H
Int J Infect Dis; 2019 Jun; 83():64-71. PubMed ID: 30951879
[TBL] [Abstract][Full Text] [Related]
20. Prognostic model for nephrotoxicity among HIV-positive Zambian adults receiving tenofovir disoproxil fumarate-based antiretroviral therapy.
Chabala FW; Siew ED; Mutale W; Mulenga L; Mweemba A; Goma F; Banda N; Kaonga P; Wester WC; Heimburger DC; Aliyu MH; Munkombwe D
PLoS One; 2021; 16(7):e0252768. PubMed ID: 34252117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
